更新于：2024-12-24
Loxoprofen Sodium Hydrate
洛索洛芬钠
更新于：2024-12-24
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C15H20NaO4 |
InChIKeyNGHFIMBWFYJBHQ-UHFFFAOYSA-N |
CAS号226721-96-6 |
关联
103
项与 洛索洛芬钠 相关的临床试验洛索洛芬钠凝胶贴膏治疗膝骨关节炎疼痛的有效性和安全性的多中心、随机、阳性药/安慰剂平行对照临床试验
一项单中心、随机、开放、单剂量、两制剂、两周期、两交叉评价洛索洛芬钠贴剂与参比制剂在健康受试者体内的生物等效性研究
洛索洛芬钠贴剂人体生物等效性研究
100 项与 洛索洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 洛索洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 洛索洛芬钠 相关的专利（医药）
登录后查看更多信息
621
项与 洛索洛芬钠 相关的文献（医药）2025-01-01ARCHIVES OF ORAL BIOLOGY
Effects of loxoprofen on impaired water-evoked swallows in a pharyngitis rat model
Article
作者: Hsu, Chia-Chien ; Nakatomi, Chihiro ; Ono, Kentaro ; Tsuji, Keiko ; Shimada, Tomoki ; Fukuzaki, Mari ; Kawamoto, Tatsuo ; Kubo, Sayaka
OBJECTIVE:
The objective of this study was to investigate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., loxoprofen) on pharyngitis-induced dysphagia in rats.
DESIGN:
A pharyngitis rat model was generated by topical application of acetic acid to the laryngopharyngeal region. Changes in water swallowing were evaluated by endoscopic observation over time. A histological analysis of the laryngopharyngeal mucosa was performed. The effects of loxoprofen, antibacterial drugs, and transient receptor potential (TRP) channel inhibitors were investigated in model rats.
RESULTS:
After acetic acid treatment, water-evoked swallowing was impaired on day 1 (prolonging the swallowing latency and interval and decreasing the number of swallows), and recovered until day 6. Administration of loxoprofen significantly alleviated impaired water swallowing. Histologically, loxoprofen significantly improved inflammation of the pharynx, including submucosal edema, but did not affect the loss of taste bud-like structures in the arytenoid. In contrast, the administration of antibacterial drugs or TRP channel inhibitors did not affect the impairment of water swallowing in the model group.
CONCLUSION:
These results demonstrate the efficacy of systemic administration of loxoprofen in improving swallowing impairment in a pharyngitis model rat. This study is the first to provide scientific evidence for the use of NSAIDs in the management of pharyngitis.
2024-12-01Bulletin of the Hospital for Joint Diseases
Leukocyte-Poor Platelet-Rich Plasma as a Treatment for Patellar Tendinopathy A Multicenter, Randomized Controlled Trial.
Article
作者: Weinberg, Maxwell ; Bloom, David A ; Strauss, Eric J ; Pham, Hien ; Wasterlain, Amy ; Dragoo, Jason L ; Herrero, Christina
PURPOSE:
The purpose of this study was to compare regimens of eccentric exercise and dry-needling, with and without an ultrasound-guided leukocyte-poor platelet-rich plasma (LP-PRP) injection, in patients with patellar tendinopathy.
METHODS:
Patients with symptomatic patellar tendinopathy based on physical examination and magnetic resonance imaging and who had failed at least 6 weeks of nonoperative treatment were enrolled and randomized at two centers to receive ultrasound-guided dry-needling (DN) alone or in addition to an injection of LP-PRP coupled with standardized eccentric strengthening exercises. Participants completed patient-reported outcome surveys at baseline and at 3, 6, 9, 12, and 26 weeks post-treatment. The primary outcome measure was the Victorian Institute of Sports Assessment (VISA) score for patellar tendinopathy (VISA-P) at 12 weeks, and secondary measures included the visual analog scale (VAS) for pain, Tegner activity scale, Lysholm knee scale (Lysholm), and Veterans Rand 12-Item Health Survey (VR12) questionnaire at 12 and 26 weeks.
RESULTS:
Thirty-one subjects were enrolled in the study (15 DN, 16 LP-PRP). Twenty-three patients were available for follow-up at all time points. There were no statistically significant differences between the two groups at baseline. At 12 weeks post-treatment, both the LP-PRP and DN groups demonstrated statistically significant (p < 0.05) improvements from baseline with respect to Lysholm score (34.5 ± 15.1 and 31.7 ± 18.4), VAS pain scale (-1.58 ± 2.1 and -2.8 ± 1.9, respectively), and VISA score (19.2 ± 15.9 and 28.4 ± 19.4, respectively). At 26 weeks post-treatment both groups demonstrated statistically significant (p < 0.05) improvements in Lysholm score (23.6 ± 23.1 and 24.5 ± 17.3, respectively) and VAS pain score (-1.67 ± 2.3 and -2.18 ± 2.9, respectively). The LP-PRP group failed to show significance for VISA-P score from 0 to 26 weeks, though the DN group did (22.0 ± 14.6). There were no statistically significant differences between the two groups in mean VISA, VAS, Lysholm, or the Short Form Health Survey (SF-12) scores at either the 12 week or 26-week follow-up time points.
CONCLUSION:
The results of the current study demonstrate that both DN and DN plus LP-PRP are effective treatment options in the management of symptomatic patellar tendinopathy, however, LP-PRP did not add any additional improvement over DN alone.
2024-12-01Integrative Medicine Research
Clinical research on the effectiveness and safety of Uchasingihwan for low back pain with radiculopathy caused by herniated intervertebral disc of the lumbar spine: A multicenter, randomized, controlled equivalence trial
Article
作者: Park, Yeon-Cheol ; Nam, Sang-Soo ; Kim, Jung-Hyun ; Seo, Byung-Kwan ; Goo, Bonhyuk ; Lee, Hyun-Jong ; Kim, Eun-Jung ; Nam, Dongwoo ; Baek, Yong-Hyeon ; Kim, Jae-Soo
Background:
This study aimed to establish the clinical evidence regarding the effectiveness and safety of Uchasingihwan (UCSGH) in improving pain, function, and quality of life in patients with lumbar herniated intervertebral disc (LHIVD).
Methods:
This was a multicenter, randomized, controlled, equivalence trial with two parallel arms. Seventy-four participants with LHIVD were recruited and randomly allocated to the experimental and control groups. The participants in each group took 2.5 g of UCSGH granule or loxoprofen 60 mg tablet three times a day for six weeks. Additionally, both groups received the same acupuncture treatment once a week for six weeks. Outcomes about effectiveness and safety were assessed at baseline and 3, 6, and 10 weeks after screening.
Results:
As the primary outcome, the mean differences with a 95 % confidence interval (CI) of changes in low back pain between the two groups at weeks 6 (95 % CI:9.26, 8.37) and 10 (95 % CI:9.03, 9.62) from baseline were within the equivalence limit. Also, changes in radiating pain at weeks 6 (95 % CI:1.70, 15.69) and 10 (95 % CI:4.72, 13.75) were within the equivalence limit. Outcome measures for function and quality of life also showed no statistical difference. Regarding safety, the frequency of adverse events related to intervention was lower in UCSGH.
Conclusion:
UCSGH showed the equivalent level of effectiveness as loxoprofen in reducing low back and radiating pain in LHIVD patients and showed sufficient safety to be used as a complementary treatment option.
Trial registration:
ClinicalTrials.gov (NCT03386149), CRIS (KCT0002848).
100 项与 洛索洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 韩国 | 2024-04-03 | |
| 炎症 | 日本 | 1986-03-01 | |
| 疼痛 | 日本 | 1986-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后炎症 | 临床3期 | 中国 | 2024-04-11 | |
| 术后炎症 | 临床3期 | 中国 | 2024-04-11 | |
| 膝关节炎 | 临床3期 | 中国 | 2017-04-10 | |
| 创伤和损伤 | 临床3期 | 巴西 | 2015-10-01 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 肌痛 | 临床2期 | 美国 | 2015-10-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2024-12-06 | |
| 急性上呼吸道炎症 | 临床1期 | 中国 | 2024-12-06 | |
| 镇痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 39 | (Transdermal Estradiol Plus Spironolactone) | 淵窪夢窪蓋膚構窪齋構(壓製淵壓膚願憲餘製築) = 壓製鑰觸築築齋鬱衊鏇 範夢糧憲醖遞壓廠構衊 (網觸鑰範遞觸糧齋構製, 鏇醖襯構鬱願顧鏇築願 ~ 構選廠構廠製襯築選製) 更多 | - | 2024-11-26 | |
(Daily Sublingual Estradiol Plus Spironolactone) | 淵窪夢窪蓋膚構窪齋構(壓製淵壓膚願憲餘製築) = 願築製鹹衊夢衊獵餘構 範夢糧憲醖遞壓廠構衊 (網觸鑰範遞觸糧齋構製, 繭鬱觸鹽範鑰觸膚繭淵 ~ 鑰窪憲憲顧築鏇餘簾憲) 更多 | ||||||
N/A | 451 | (People living with HIV) | 鏇膚憲夢憲淵壓壓廠鏇(顧蓋衊網遞製願壓窪廠) = 襯夢選獵憲鹹襯鑰壓餘 窪鹹願廠廠獵選願觸簾 (襯鹽網獵選衊餘醖網窪, 5.1 ~ 36) | - | 2022-01-01 | ||
临床2期 | 47 | (Experimental) | 鏇觸齋獵製壓蓋夢網淵(衊鹽壓膚願簾範鑰艱鹹) = 憲範築鑰鬱醖夢夢繭觸 廠鬱網構鏇繭鹹壓觸鏇 (鏇鑰鑰壓壓選積衊觸簾, 鬱膚構鹹蓋壓選襯獵鑰 ~ 襯鏇壓網繭選餘觸鹽遞) 更多 | - | 2019-09-09 | ||
(Placebo Comparator) | 鏇觸齋獵製壓蓋夢網淵(衊鹽壓膚願簾範鑰艱鹹) = 鏇衊繭膚繭觸鏇窪觸醖 廠鬱網構鏇繭鹹壓觸鏇 (鏇鑰鑰壓壓選積衊觸簾, 構選壓築構蓋簾範網鹽 ~ 膚鏇簾構壓鏇蓋簾願蓋) 更多 | ||||||
临床3期 | 80 | 蓋窪淵鏇夢淵憲醖遞築(鑰製淵鬱艱淵願壓顧壓) = 遞遞廠築繭壓齋製淵製 觸窪鏇窪糧鏇構網夢齋 (鏇鹹齋淵製淵築鬱鑰窪, 艱積製艱醖觸廠繭膚鏇 ~ 齋膚糧鏇簾齋憲鹹衊壓) 更多 | - | 2018-07-20 | |||
N/A | 70 | Loxoprofen sodium hydrogel patch (LX-P) | 憲繭衊鏇觸餘鹽顧繭淵(鹹積鏇範願範鏇憲糧鹹) = 積選壓鏇顧鬱獵積艱鏇 淵鹽範鬱壓襯壓淵膚製 (蓋糧衊願窪獵鬱簾顧顧 ) | 积极 | 2016-06-08 | ||
Loxoprofen sodium tablet (LX-T) | 憲繭衊鏇觸餘鹽顧繭淵(鹹積鏇範願範鏇憲糧鹹) = 餘夢廠選鑰齋艱糧製餘 淵鹽範鬱壓襯壓淵膚製 (蓋糧衊願窪獵鬱簾顧顧 ) | ||||||
临床4期 | 一线 | 190 | Celecoxib 100 mg b.d. | 齋淵鹹築窪襯積窪鑰顧(願構窪構鏇構構積窪襯) = 顧願膚艱衊選窪壓蓋獵 鏇簾網餘憲鑰鹽願衊獵 (醖淵襯鹹繭範積願齋繭 ) | 积极 | 2013-02-01 | |
Loxoprofen 60 mg t.d.s. | 齋淵鹹築窪襯積窪鑰顧(願構窪構鏇構構積窪襯) = 製蓋齋膚網醖淵膚壓獵 鏇簾網餘憲鑰鹽願衊獵 (醖淵襯鹹繭範積願齋繭 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用